Santhera is a Swiss specialty pharmaceuti- cal company focused on the development and commercialization of products for the treatment of mitochondrial and neuromuscular diseases, areas which include many orphan and niche indications with no current therapy.

Santhera has a late-stage development pipeline in orphan indications. In Europe, Santhera plans to submit a marketing authorization application (MAA) for Raxone® as first treatment option for patients suffering from Leber's Hereditary Optic Neuropathy.

Santhera is currently recruiting patients for clinical studies in Duchenne Muscular Dystrophy, MELAS syndrome and Primary Progressive Multiple Sclerosis.